Intrinsic value of CareDx - CDNA

Previous Close

$6.31

  Intrinsic Value

$0.04

stock screener

  Rating & Target

str. sell

-99%

Previous close

$6.31

 
Intrinsic value

$0.04

 
Up/down potential

-99%

 
Rating

str. sell

We calculate the intrinsic value of CDNA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  46.43
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  41
  42
  43
  44
  45
  46
  48
  50
  51
  53
  55
  58
  60
  62
  65
  68
  71
  74
  77
  81
  84
  88
  93
  97
  101
  106
  111
  117
  122
  128
  134
Variable operating expenses, $m
 
  60
  62
  63
  65
  67
  69
  71
  74
  76
  79
  81
  84
  88
  91
  95
  99
  104
  109
  113
  119
  124
  130
  136
  143
  149
  156
  164
  172
  180
  189
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  78
  60
  62
  63
  65
  67
  69
  71
  74
  76
  79
  81
  84
  88
  91
  95
  99
  104
  109
  113
  119
  124
  130
  136
  143
  149
  156
  164
  172
  180
  189
Operating income, $m
  -37
  -18
  -19
  -19
  -20
  -20
  -21
  -21
  -22
  -23
  -24
  -23
  -24
  -25
  -26
  -27
  -29
  -30
  -31
  -33
  -34
  -36
  -37
  -39
  -41
  -43
  -45
  -47
  -50
  -52
  -54
EBITDA, $m
  -34
  -15
  -15
  -16
  -16
  -17
  -17
  -18
  -19
  -19
  -20
  -21
  -22
  -22
  -23
  -24
  -26
  -27
  -28
  -29
  -30
  -32
  -33
  -35
  -37
  -38
  -40
  -42
  -44
  -46
  -48
Interest expense (income), $m
  1
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  4
  4
  4
  4
  5
Earnings before tax, $m
  -41
  -19
  -19
  -20
  -20
  -21
  -21
  -22
  -23
  -24
  -25
  -24
  -25
  -27
  -28
  -29
  -30
  -32
  -33
  -35
  -37
  -38
  -40
  -42
  -44
  -46
  -49
  -51
  -54
  -56
  -59
Tax expense, $m
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -39
  -19
  -19
  -20
  -20
  -21
  -21
  -22
  -23
  -24
  -25
  -24
  -25
  -27
  -28
  -29
  -30
  -32
  -33
  -35
  -37
  -38
  -40
  -42
  -44
  -46
  -49
  -51
  -54
  -56
  -59

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  17
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  77
  61
  63
  64
  66
  68
  70
  73
  75
  78
  81
  84
  88
  91
  95
  99
  104
  108
  113
  118
  124
  129
  135
  142
  149
  156
  163
  171
  179
  188
  197
Adjusted assets (=assets-cash), $m
  60
  61
  63
  64
  66
  68
  70
  73
  75
  78
  81
  84
  88
  91
  95
  99
  104
  108
  113
  118
  124
  129
  135
  142
  149
  156
  163
  171
  179
  188
  197
Revenue / Adjusted assets
  0.683
  0.689
  0.683
  0.688
  0.682
  0.676
  0.686
  0.685
  0.680
  0.679
  0.679
  0.690
  0.682
  0.681
  0.684
  0.687
  0.683
  0.685
  0.681
  0.686
  0.677
  0.682
  0.689
  0.683
  0.678
  0.679
  0.681
  0.684
  0.682
  0.681
  0.680
Average production assets, $m
  20
  20
  21
  21
  22
  23
  23
  24
  25
  26
  27
  28
  29
  30
  32
  33
  35
  36
  38
  39
  41
  43
  45
  47
  50
  52
  54
  57
  60
  63
  66
Working capital, $m
  -14
  -8
  -8
  -9
  -9
  -9
  -9
  -10
  -10
  -10
  -11
  -11
  -12
  -12
  -13
  -13
  -14
  -14
  -15
  -16
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
Total debt, $m
  24
  8
  9
  10
  11
  12
  14
  16
  17
  19
  21
  24
  26
  28
  31
  34
  37
  40
  43
  47
  50
  54
  59
  63
  67
  72
  77
  83
  88
  94
  100
Total liabilities, $m
  57
  42
  43
  44
  45
  46
  48
  50
  51
  53
  55
  58
  60
  62
  65
  68
  71
  74
  77
  81
  84
  88
  93
  97
  101
  106
  111
  117
  122
  128
  134
Total equity, $m
  19
  19
  20
  20
  21
  22
  22
  23
  24
  25
  26
  27
  28
  29
  30
  31
  33
  34
  36
  37
  39
  41
  43
  45
  47
  49
  52
  54
  57
  60
  62
Total liabilities and equity, $m
  76
  61
  63
  64
  66
  68
  70
  73
  75
  78
  81
  85
  88
  91
  95
  99
  104
  108
  113
  118
  123
  129
  136
  142
  148
  155
  163
  171
  179
  188
  196
Debt-to-equity ratio
  1.263
  0.400
  0.440
  0.490
  0.530
  0.580
  0.630
  0.680
  0.730
  0.780
  0.830
  0.880
  0.930
  0.980
  1.030
  1.070
  1.120
  1.160
  1.210
  1.250
  1.290
  1.330
  1.360
  1.400
  1.430
  1.470
  1.500
  1.530
  1.560
  1.580
  1.610
Adjusted equity ratio
  0.033
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317
  0.317

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -39
  -19
  -19
  -20
  -20
  -21
  -21
  -22
  -23
  -24
  -25
  -24
  -25
  -27
  -28
  -29
  -30
  -32
  -33
  -35
  -37
  -38
  -40
  -42
  -44
  -46
  -49
  -51
  -54
  -56
  -59
Depreciation, amort., depletion, $m
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
Funds from operations, $m
  -14
  -15
  -16
  -16
  -17
  -17
  -18
  -19
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -30
  -31
  -33
  -34
  -36
  -38
  -40
  -42
  -44
  -46
  -48
  -51
  -53
Change in working capital, $m
  3
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from operations, $m
  -17
  -15
  -16
  -16
  -17
  -17
  -18
  -18
  -19
  -20
  -21
  -21
  -22
  -23
  -24
  -25
  -27
  -28
  -29
  -31
  -32
  -34
  -35
  -37
  -39
  -41
  -43
  -45
  -47
  -49
  -52
Maintenance CAPEX, $m
  0
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
New CAPEX, $m
  -1
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
Cash from investing activities, $m
  -21
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -6
  -7
  -7
  -8
  -8
  -8
  -9
Free cash flow, $m
  -38
  -17
  -18
  -18
  -19
  -20
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -30
  -31
  -33
  -34
  -36
  -37
  -39
  -41
  -43
  -45
  -48
  -50
  -52
  -55
  -58
  -61
Issuance/(repayment) of debt, $m
  17
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
Issuance/(repurchase) of shares, $m
  8
  19
  20
  20
  21
  21
  22
  23
  24
  25
  26
  25
  26
  28
  29
  30
  32
  33
  35
  36
  38
  40
  42
  44
  46
  49
  51
  54
  56
  59
  62
Cash from financing (excl. dividends), $m  
  25
  20
  21
  21
  22
  22
  24
  25
  26
  27
  28
  27
  28
  30
  32
  33
  35
  36
  38
  40
  42
  44
  46
  48
  51
  54
  56
  59
  62
  65
  68
Total cash flow (excl. dividends), $m
  -13
  2
  3
  3
  3
  3
  3
  3
  4
  4
  4
  3
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  7
  7
  7
  8
Retained Cash Flow (-), $m
  10
  -19
  -20
  -20
  -21
  -21
  -22
  -23
  -24
  -25
  -26
  -25
  -26
  -28
  -29
  -30
  -32
  -33
  -35
  -36
  -38
  -40
  -42
  -44
  -46
  -49
  -51
  -54
  -56
  -59
  -62
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -17
  -17
  -17
  -18
  -18
  -19
  -20
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -31
  -32
  -34
  -35
  -37
  -39
  -41
  -43
  -45
  -47
  -49
  -52
  -54
Discount rate, %
 
  6.90
  7.25
  7.61
  7.99
  8.39
  8.81
  9.25
  9.71
  10.19
  10.70
  11.24
  11.80
  12.39
  13.01
  13.66
  14.34
  15.06
  15.81
  16.61
  17.44
  18.31
  19.22
  20.18
  21.19
  22.25
  23.37
  24.53
  25.76
  27.05
  28.40
PV of cash for distribution, $m
 
  -16
  -15
  -14
  -13
  -12
  -11
  -11
  -10
  -9
  -8
  -7
  -6
  -5
  -5
  -4
  -3
  -3
  -2
  -2
  -1
  -1
  -1
  -1
  0
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  90.3
  81.6
  73.6
  66.4
  59.9
  54.0
  48.6
  43.8
  39.5
  35.5
  32.1
  29.1
  26.3
  23.7
  21.4
  19.4
  17.5
  15.8
  14.2
  12.8
  11.6
  10.4
  9.4
  8.5
  7.6
  6.9
  6.2
  5.6
  5.0
  4.5

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

FINANCIAL RATIOS  of  CareDx (CDNA)

Valuation Ratios
P/E Ratio -3.4
Price to Sales 3.3
Price to Book 7.1
Price to Tangible Book
Price to Cash Flow -7.9
Price to Free Cash Flow -7.5
Growth Rates
Sales Growth Rate 46.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 1
Current Ratio 0
LT Debt to Equity 5.3%
Total Debt to Equity 126.3%
Interest Coverage -40
Management Effectiveness
Return On Assets -57.2%
Ret/ On Assets - 3 Yr. Avg. -26.5%
Return On Total Capital -88.6%
Ret/ On T. Cap. - 3 Yr. Avg. -37.9%
Return On Equity -162.5%
Return On Equity - 3 Yr. Avg. -64.9%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 48.8%
Gross Margin - 3 Yr. Avg. 61.1%
EBITDA Margin -90.2%
EBITDA Margin - 3 Yr. Avg. -43.1%
Operating Margin -90.2%
Oper. Margin - 3 Yr. Avg. -43.1%
Pre-Tax Margin -100%
Pre-Tax Margin - 3 Yr. Avg. -51.2%
Net Profit Margin -95.1%
Net Profit Margin - 3 Yr. Avg. -47.1%
Effective Tax Rate 2.4%
Eff/ Tax Rate - 3 Yr. Avg. 67.5%
Payout Ratio 0%

CDNA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CDNA stock intrinsic value calculation we used $41 million for the last fiscal year's total revenue generated by CareDx. The default revenue input number comes from 2016 income statement of CareDx. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CDNA stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.9%, whose default value for CDNA is calculated based on our internal credit rating of CareDx, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of CareDx.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CDNA stock the variable cost ratio is equal to 143.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CDNA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5% for CareDx.

Corporate tax rate of 27% is the nominal tax rate for CareDx. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CDNA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CDNA are equal to 48.8%.

Life of production assets of 11 years is the average useful life of capital assets used in CareDx operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CDNA is equal to -19.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $19 million for CareDx - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 28.253 million for CareDx is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of CareDx at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
FMI Foundation Med 67.25 1.13  str.sell
TMO Thermo Fisher 213.51 70.89  str.sell
GHDX Genomic Health 33.88 1.09  str.sell
MYGN Myriad Genetic 38.62 33.23  hold
OPGN OpGen 3.31 0.01  str.sell
QGEN Qiagen 32.87 16.98  sell
GNMK GenMark Diagno 4.83 0.17  str.sell

COMPANY NEWS

▶ TRIO Honors Peter Maag with Transplant Innovation Award   [Jan-16-18 09:00AM  GlobeNewswire]
▶ 4 Top-Ranked Growth Stocks in MedTech Under $20   [Nov-30-17 02:54PM  Zacks]
▶ ETFs with exposure to CareDx, Inc. : November 27, 2017   [Nov-27-17 12:38PM  Capital Cube]
▶ CMS Releases 2018 Clinical Laboratory Fee Schedule   [Nov-20-17 08:00AM  GlobeNewswire]
▶ ETFs with exposure to CareDx, Inc. : November 17, 2017   [Nov-17-17 11:33AM  Capital Cube]
▶ CareDx Further Simplifies its Balance Sheet   [Nov-15-17 09:00AM  GlobeNewswire]
▶ CareDx reports 3Q loss   [Nov-09-17 04:16PM  Associated Press]
▶ CareDx, Inc. to Host Earnings Call   [12:30PM  ACCESSWIRE]
▶ ETFs with exposure to CareDx, Inc. : November 7, 2017   [Nov-07-17 09:54AM  Capital Cube]
▶ CareDx to Participate in Upcoming Investor Conferences   [Nov-02-17 09:00AM  GlobeNewswire]
▶ AlloSure data will be presented at ASN   [Oct-30-17 08:00AM  GlobeNewswire]
▶ CareDx Announces Closing of Public Offering of Common Stock   [Oct-10-17 04:00PM  GlobeNewswire]
▶ How Does CareDx Inc (CDNA) Affect Your Portfolio Returns?   [Oct-05-17 07:45PM  Simply Wall St.]
▶ MolDX sets AlloSure reimbursement at 2017 AlloMap level   [Sep-26-17 08:30AM  GlobeNewswire]
▶ ETFs with exposure to CareDx, Inc. : September 25, 2017   [Sep-25-17 10:35AM  Capital Cube]
▶ AlloMaps Medicare reimbursement to increase in 2018   [Sep-22-17 05:26PM  GlobeNewswire]
▶ Have Investors Already Priced In CareDx Incs (CDNA) Growth?   [Sep-21-17 06:51PM  Simply Wall St.]
▶ This Market Knows No Fear   [01:41PM  TheStreet.com]
▶ ETFs with exposure to CareDx, Inc. : September 14, 2017   [Sep-14-17 06:04PM  Capital Cube]
▶ CareDx to Participate in Upcoming Investor Conferences   [Aug-15-17 08:00AM  GlobeNewswire]
▶ CareDx reports 2Q loss   [Aug-10-17 09:43PM  Associated Press]
▶ CareDx reports 2Q loss   [04:43PM  Associated Press]
▶ ETFs with exposure to CareDx, Inc. : July 10, 2017   [Jul-10-17 02:08PM  Capital Cube]
▶ ETFs with exposure to CareDx, Inc. : June 28, 2017   [Jun-28-17 02:38PM  Capital Cube]
▶ ETFs with exposure to CareDx, Inc. : June 16, 2017   [Jun-16-17 03:31PM  Capital Cube]
▶ CareDx reports 1Q loss   [Jun-09-17 09:04AM  Associated Press]
▶ CareDx Announces Receipt of Expected Letter from Nasdaq   [May-22-17 05:43PM  GlobeNewswire]
▶ CareDx to Present Key AlloSure Validation Data at ATC   [Apr-28-17 04:01PM  GlobeNewswire]
▶ CareDx reports 4Q loss   [Apr-21-17 05:52PM  Associated Press]
▶ CareDx to Present New Data on AlloMap and AlloSure at ISHLT   [Apr-03-17 04:01PM  GlobeNewswire]
▶ CareDx Closes New $25 Million Debt Facility   [04:01PM  GlobeNewswire]
▶ AlloSure Featured in Journal of Applied Laboratory Medicine   [Mar-14-17 04:01PM  GlobeNewswire]
▶ ETFs with exposure to CareDx, Inc. : December 8, 2016   [Dec-08-16 02:24PM  Capital Cube]
▶ CareDx to Participate in Upcoming Investor Conferences   [Nov-08-16 04:01PM  GlobeNewswire]
▶ CareDx to present AlloSure® data at AMP in Charlotte, NC   [Nov-03-16 04:02PM  GlobeNewswire]
▶ CareDx Announces First Commercial Sale of Olerup QTYPE   [Oct-24-16 04:01PM  GlobeNewswire]
▶ CareDx Launches Olerup QTYPE® at ASHI   [Sep-28-16 05:06PM  GlobeNewswire]
Financial statements of CDNA
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.